Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Javaherian

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
AIDS Research and Human Retroviruses|June 1, 1988
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoproteinM A Skinner, R Ting, A J Langlois, et al.
Journal of Virology|June 1, 1988
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitopeS Matsushita, M Robert-Guroff, J Rusche, et al.
AIDS Research and Human Retroviruses|March 1, 1990
C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individualsY Devash, T J Matthews, J E Drummond, et al.
Science (New York, N.Y.)|December 14, 1990
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1K Javaherian, A J Langlois, G J LaRosa, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1988
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120J R Rusche, K Javaherian, C McDanal, et al.
International Immunology|January 1, 1989
T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restrictionP M Hale, K B Cease, R A Houghten, et al.
Journal of the National Cancer Institute|March 10, 2001
Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in miceW D Beecken, A Fernandez, A M Joussen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 1992
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1K Javaherian, A J Langlois, S Schmidt, et al.
Cancer Gene Therapy|February 4, 2006
Endostatin therapy reveals a U-shaped curve for antitumor activityR M Tjin Tham Sjin, J Naspinski, A E Birsner, et al.
Journal of Virology|April 1, 1994
Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinK Javaherian, A J Langlois, D C Montefiori, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
AIDS Research and Human Retroviruses|June 1, 1988
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoproteinM A Skinner, R Ting, A J Langlois, et al.
Journal of Virology|June 1, 1988
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitopeS Matsushita, M Robert-Guroff, J Rusche, et al.
AIDS Research and Human Retroviruses|March 1, 1990
C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individualsY Devash, T J Matthews, J E Drummond, et al.
Science (New York, N.Y.)|December 14, 1990
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1K Javaherian, A J Langlois, G J LaRosa, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1988
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120J R Rusche, K Javaherian, C McDanal, et al.
International Immunology|January 1, 1989
T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restrictionP M Hale, K B Cease, R A Houghten, et al.
Journal of the National Cancer Institute|March 10, 2001
Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in miceW D Beecken, A Fernandez, A M Joussen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 1992
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1K Javaherian, A J Langlois, S Schmidt, et al.
Cancer Gene Therapy|February 4, 2006
Endostatin therapy reveals a U-shaped curve for antitumor activityR M Tjin Tham Sjin, J Naspinski, A E Birsner, et al.
Journal of Virology|April 1, 1994
Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinK Javaherian, A J Langlois, D C Montefiori, et al.
Pageof 4